Trial Profile
Phase II study of dasatinib (BMS-354825) for advanced 'triple-negative' breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 09 Oct 2008 Checked against the ClinicalTrials.gov record.
- 28 Sep 2008 Actual number of patients enrolled was 44 according to the ClinicalTrials.gov record.
- 28 Sep 2008 Status changed from active, no longer recruiting to completed according to the ClinicalTrials.gov record.